Surgical Margin Status Has No Effect on Prostate Cancer Survival

Share this content:
Positive surgical margins alone do not influence overall survival among prostate cancer patients undergoing RP.
Positive surgical margins alone do not influence overall survival among prostate cancer patients undergoing RP.

NEW ORLEANS—Positive surgical margins (PSMs) alone do not influence overall survival among prostate cancer patients undergoing radical prostatectomy (RP), investigators reported at the American Urological Association annual meeting.

Alexa Meyer, MD, and collaborators at Columbia University in New York identified 3,252 patients who underwent RP. The group included 830, 1,746, and 676 patients with low-, intermediate-, and high-risk disease, respectively. The median follow-up was 94.2 months.

While the overall PSM rate was 26.8%, it was 14.6%, 27.5%, and 39.9% in the low-, intermediate-, and high-risk groups, respectively. The overall median survival was significantly lower for the PSM than the negative margin group (20.14 vs. 20.58 years).

The median survival also differed significantly among the 3 risk groups. It was 20.33 and 19.52 years for the intermediate- and high-risk groups, respectively, and was not yet reached for the low-risk group. Within each risk group, however, PSMs had no impact on survival.

RELATED: Prostate Cancer Metastasis Predictors in Active Surveillance Patients Identified

When controlling for adverse features, PSMs are not independently associated with survival, the researchers concluded in a poster presentation.

“This suggests that margin status is a surrogate for established risk criteria and disease biology, and should not be interpreted as a unique prognostic facture.”

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs